NBIX

$146.100.19%-0.28

Dopo l'orario di chiusura: 143.00-3.10 -2.12%

Neurocrine Biosciences Inc (NBIX)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$146.38

Aprire:

$147.13

Volume 24 ore:

1,321,060

Volume relativo:

1.19

Capitalizzazione di mercato:

$14.85B

Reddito:

$3.10B

Utile/perdita netta:

$668.60M

Rapporto P/E:

22.46

EPS:

$6.50

Flusso di cassa netto:

$831.30M

1W Prestazione:

+2.38%

1M Prestazione:

+3.00%

6M Prestazione:

+10.96%

1Y Prestazione:

+5.84%

Intervallo 1D:

$145.22$149.25

Intervallo di 1 settimana:

$142.34$149.25

Portata 52W:

$122.14$186.12

Profilo aziendale di Neurocrine Biosciences Inc (NBIX)

Nome

Neurocrine Biosciences Inc

Settore

Healthcare

Industria

Drug Manufacturers - Specialty & Generic

Telefono

(858) 617-7600

Indirizzo

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, USA

Dipendente

2,000

Prossima data di guadagno

2026-11-02

Ultimi documenti SEC

SEC

Discussioni di NBIX su X

Confronta NBIX con TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NBIX Neurocrine Biosciences Inc	$146.10	$14.85B	$3.10B	$668.60M	$831.30M	$6.50
TAK Takeda Pharmaceutical Co Adr	$20.91	$66.81B	$29.91B	$1.30B	$3.49B	$0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	$42.09	$49.09B	$17.53B	$1.58B	$444.18M	$1.35
HLN Haleon Plc Adr	$8.66	$38.08B	$14.54B	$2.22B	$2.58B	$0.4871
ZTS Zoetis Inc	$79.72	$32.94B	$9.51B	$2.64B	$2.14B	$6.04
UTHR United Therapeutics Corp	$598.72	$25.68B	$3.17B	$1.29B	$1.01B	$27.09

Neurocrine Biosciences Inc Azioni (NBIX) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-06	Resumed	Guggenheim	Buy
2026-06-02	Resumed	Goldman	Buy
2026-05-22	Iniziato	Bernstein	Outperform
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-10-21	Iniziato	Citigroup	Buy
2025-07-21	Iniziato	Truist	Buy
2025-07-10	Iniziato	Goldman	Buy
2025-04-15	Aggiornamento	Needham	Hold → Buy
2025-04-14	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Iniziato	Deutsche Bank	Hold
2024-10-10	Resumed	Raymond James	Outperform
2024-08-29	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-04-24	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-12-13	Resumed	Citigroup	Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-24	Resumed	Cantor Fitzgerald	Overweight
2023-08-21	Reiterato	Mizuho	Neutral
2023-07-24	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-07-06	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-30	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-03-03	Aggiornamento	Evercore ISI	In-line → Outperform
2023-02-03	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Downgrade	Evercore ISI	Outperform → In-line
2022-10-11	Iniziato	UBS	Buy
2022-09-26	Iniziato	Wells Fargo	Equal Weight
2022-06-06	Resumed	Jefferies	Buy
2022-03-03	Downgrade	Piper Sandler	Overweight → Neutral
2022-02-25	Aggiornamento	Goldman	Neutral → Buy
2022-01-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Iniziato	BMO Capital Markets	Underperform
2021-11-17	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Resumed	Needham	Hold
2021-08-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-05-18	Resumed	Goldman	Neutral
2021-05-06	Aggiornamento	Barclays	Equal Weight → Overweight
2021-02-02	Iniziato	Raymond James	Outperform
2020-09-30	Iniziato	The Benchmark Company	Hold
2020-08-04	Downgrade	JP Morgan	Overweight → Neutral
2020-06-29	Downgrade	Goldman	Buy → Neutral
2020-06-09	Iniziato	Wedbush	Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-02-24	Iniziato	William Blair	Outperform
2020-02-06	Iniziato	Mizuho	Neutral
2020-02-05	Reiterato	H.C. Wainwright	Buy
2019-12-13	Downgrade	Credit Suisse	Outperform → Neutral
2019-08-07	Iniziato	RBC Capital Mkts	Outperform
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-05	Iniziato	Guggenheim	Neutral
2019-05-21	Iniziato	Credit Suisse	Outperform
2019-04-22	Aggiornamento	JP Morgan	Neutral → Overweight
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-02-06	Reiterato	BofA/Merrill	Buy
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-12-13	Iniziato	Goldman	Buy
2018-11-21	Iniziato	Canaccord Genuity	Buy

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Neurocrine Biosciences Inc Azioni (NBIX) insider trading

Boyer David W.Sep 14 '26
Chief Corp. Affairs Officer
Transazione
Sale
Costo
$157.45
#Azioni
826
Valore ($)
130,051
#Azioni Totale
8,722
DAVID WARREN BOYERSep 14 '26
Officer
Transazione
Proposed Sale
Costo
$156.22
#Azioni
4,714
Valore ($)
736,421
#Azioni Totale
0
MATTHEW C ABERNETHYSep 14 '26
Officer
Transazione
Proposed Sale
Costo
$156.22
#Azioni
2,311
Valore ($)
361,024
#Azioni Totale
0
ABERNETHY MATTSep 14 '26
Chief Financial Officer
Transazione
Sale
Costo
$157.20
#Azioni
2,311
Valore ($)
363,285
#Azioni Totale
42,808
BENEVICH ERICSep 09 '26
Chief Commercial Officer
Transazione
Option Exercise
Costo
$43.24
#Azioni
3,194
Valore ($)
138,109
#Azioni Totale
66,562
BENEVICH ERICSep 09 '26
Chief Commercial Officer
Transazione
Sale
Costo
$154.61
#Azioni
2,154
Valore ($)
333,030
#Azioni Totale
64,408
ERIC BENEVICHSep 09 '26
Officer
Transazione
Proposed Sale
Costo
$155.13
#Azioni
2,154
Valore ($)
334,150
#Azioni Totale
0
Norwalk Leslie VJul 29 '26
Director
Transazione
Option Exercise
Costo
$139.43
#Azioni
842
Valore ($)
117,400
#Azioni Totale
2,430
Norwalk Leslie VJul 28 '26
Director
Transazione
Sale
Costo
$182.01
#Azioni
1,250
Valore ($)
227,508
#Azioni Totale
1,588
INGRID DELAETJul 10 '26
Officer
Transazione
Proposed Sale
Costo
$180.55
#Azioni
4,367
Valore ($)
788,462
#Azioni Totale
0

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Boyer David W.	Chief Corp. Affairs Officer	Sep 14 '26	Sale	$157.45	826	130,051	8,722
DAVID WARREN BOYER	Officer	Sep 14 '26	Proposed Sale	$156.22	4,714	736,421	0
MATTHEW C ABERNETHY	Officer	Sep 14 '26	Proposed Sale	$156.22	2,311	361,024	0
ABERNETHY MATT	Chief Financial Officer	Sep 14 '26	Sale	$157.20	2,311	363,285	42,808
BENEVICH ERIC	Chief Commercial Officer	Sep 09 '26	Option Exercise	$43.24	3,194	138,109	66,562
BENEVICH ERIC	Chief Commercial Officer	Sep 09 '26	Sale	$154.61	2,154	333,030	64,408
ERIC BENEVICH	Officer	Sep 09 '26	Proposed Sale	$155.13	2,154	334,150	0
Norwalk Leslie V	Director	Jul 29 '26	Option Exercise	$139.43	842	117,400	2,430
Norwalk Leslie V	Director	Jul 28 '26	Sale	$182.01	1,250	227,508	1,588
INGRID DELAET	Officer	Jul 10 '26	Proposed Sale	$180.55	4,367	788,462	0

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

Oct 29, 2026

Neurocrine Biosciences stock: Q3 results set for November 2 - ad-hoc-news.de

Oct 29, 2026

Oct 28, 2026

Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill

Oct 28, 2026

Oct 27, 2026

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research

Oct 27, 2026

Healthcare stocks with strong revenue growth and attractive valuations - TradingView

Oct 27, 2026

Oct 26, 2026

Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope - Finviz

Oct 26, 2026

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia - PR Newswire

Oct 26, 2026

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research

Oct 26, 2026

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 26, 2026

Oct 25, 2026

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome - PR Newswire

Oct 22, 2026

Oct 21, 2026